中医临床研究
中醫臨床研究
중의림상연구
Clinical Journal of Chinese Medicine
2015年
30期
90-94
,共5页
2型糖尿病大血管病变%通脉降脂丸%氧化应激
2型糖尿病大血管病變%通脈降脂汍%氧化應激
2형당뇨병대혈관병변%통맥강지환%양화응격
Type II diabetes mellitus macrovascular complications%Tongmai Jiangzhi pill%Oxidative stress
目的:观察通脉降脂丸对糖尿病模型大鼠 2 型糖尿病大血管病变氧化应激的影响.方法:采用对 4 个月龄雄性Wistar大鼠一次性腹腔注射STZ结合饮水添加Nω-硝基-L-精氨酸甲酯(L-NAME)0.1 mg·mL-1·d-1及高脂饲料喂饲的方法复制2型糖尿病大血管病变模型.成模后大鼠随机分成模型组、阿托伐他汀钙组、通脉降脂丸组,另设15只正常Wistar大鼠为正常对照组.给药时间30 d.实验结束后测定大鼠血检测血清F2-异前列烷、血清超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、丙二醛(MAD)、总抗氧化能力(T-AOC)等活性水平;检测醛糖还原酶AR、NADPH氧化酶亚基的活性;RT-PCR法测定主动脉NADPH氧化酶亚基p22phox mRNA及p47phox mRNA表达.结果:通脉降脂丸组大鼠血清SOD、GSH-Px、T-AOC等活性较模型组升高(P<0.05),阿托伐他汀和通脉降脂丸均能降低主动脉p47phox mRNA、p22phox mRNA的表达水平(P<0.05).结论:通脉降脂丸可提高糖尿病GK大鼠血清SOD、GSH-Px、T-AOC活性,下调主动脉p47phox mRNA、p22phox mRNA表达,可能因此减轻糖尿病大血管病变机体的氧化应激水平,这可能是通脉降脂丸治疗T2DM大血管病变的可能机制之一.
目的:觀察通脈降脂汍對糖尿病模型大鼠 2 型糖尿病大血管病變氧化應激的影響.方法:採用對 4 箇月齡雄性Wistar大鼠一次性腹腔註射STZ結閤飲水添加Nω-硝基-L-精氨痠甲酯(L-NAME)0.1 mg·mL-1·d-1及高脂飼料餵飼的方法複製2型糖尿病大血管病變模型.成模後大鼠隨機分成模型組、阿託伐他汀鈣組、通脈降脂汍組,另設15隻正常Wistar大鼠為正常對照組.給藥時間30 d.實驗結束後測定大鼠血檢測血清F2-異前列烷、血清超氧化物歧化酶(SOD)、穀胱甘肽過氧化物酶(GSH-Px)、丙二醛(MAD)、總抗氧化能力(T-AOC)等活性水平;檢測醛糖還原酶AR、NADPH氧化酶亞基的活性;RT-PCR法測定主動脈NADPH氧化酶亞基p22phox mRNA及p47phox mRNA錶達.結果:通脈降脂汍組大鼠血清SOD、GSH-Px、T-AOC等活性較模型組升高(P<0.05),阿託伐他汀和通脈降脂汍均能降低主動脈p47phox mRNA、p22phox mRNA的錶達水平(P<0.05).結論:通脈降脂汍可提高糖尿病GK大鼠血清SOD、GSH-Px、T-AOC活性,下調主動脈p47phox mRNA、p22phox mRNA錶達,可能因此減輕糖尿病大血管病變機體的氧化應激水平,這可能是通脈降脂汍治療T2DM大血管病變的可能機製之一.
목적:관찰통맥강지환대당뇨병모형대서 2 형당뇨병대혈관병변양화응격적영향.방법:채용대 4 개월령웅성Wistar대서일차성복강주사STZ결합음수첨가Nω-초기-L-정안산갑지(L-NAME)0.1 mg·mL-1·d-1급고지사료위사적방법복제2형당뇨병대혈관병변모형.성모후대서수궤분성모형조、아탁벌타정개조、통맥강지환조,령설15지정상Wistar대서위정상대조조.급약시간30 d.실험결속후측정대서혈검측혈청F2-이전렬완、혈청초양화물기화매(SOD)、곡광감태과양화물매(GSH-Px)、병이철(MAD)、총항양화능력(T-AOC)등활성수평;검측철당환원매AR、NADPH양화매아기적활성;RT-PCR법측정주동맥NADPH양화매아기p22phox mRNA급p47phox mRNA표체.결과:통맥강지환조대서혈청SOD、GSH-Px、T-AOC등활성교모형조승고(P<0.05),아탁벌타정화통맥강지환균능강저주동맥p47phox mRNA、p22phox mRNA적표체수평(P<0.05).결론:통맥강지환가제고당뇨병GK대서혈청SOD、GSH-Px、T-AOC활성,하조주동맥p47phox mRNA、p22phox mRNA표체,가능인차감경당뇨병대혈관병변궤체적양화응격수평,저가능시통맥강지환치료T2DM대혈관병변적가능궤제지일.
Objective: To study the effect of Tongmai Jiangzhi pill (TMJZ) on the oxidative stress in Wistar rats with T2DM Macroangiopathy.Methods: 4-month-old male Wistar rats considered for the experiment and they were given intraperitoneal injection of STZ and Nω-nitro-L-arginine methyl ester (L-NAME) added into the drinking water plus high fat diet to prepare rats model with diabetic vascular disease.Wistar rats were divided into model group,atorvastatin group,TMJZ group and another 15 Wistar rats act as the normal group.After 30 days of treatment,Antioxidant enzymes was examined with colorimetry while the mRNA expression of p22phox and p47phox in thoracic aorta vessel wall were measured by real-time PCR.Results: The TMJZ group had significantly higher activity of SOD,GSH-Px and T-AOC compared with model group,and higher activity of both SOD and GSH-Px compared with atorvastatin group.Compared with model group,the mRNA expression of p47phox and p22phox decreased in atorvastatin group and TMJZ group.Conclusion: Tongmai Jiangzhi pill can improve the activities of antioxidant enzymes (including SOD,GSH-Px and T-AOC) and significantly reduce the mRNA expression of p47phox and p22phox in aorta in Wistar rats with T2DM.So,Macroangiopathy by Tongmai Jiangzhi pill maybe one of the possible curing mechanisms that inhibit the oxidative stress and preventsT2DM in human body also.
